Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
1. A solid pharmaceutical composition for oral administration comprising: 0.5 to 2.5 μmol N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib 8,Arg34]GLP-1(7-37) and 0.8-1.3 mmol of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the solid pharmaceutical composition has surface eroding or co-release properties, and a disintegration time of 7-15 minutes.
2. The composition according to claim 1 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.
3. The composition according to claim 2 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).
4. The composition according to claim 3 , wherein said composition is in the form of a tablet.
5. The composition according to claim 4 , wherein said tablet has a weight between 300-500 mg.
6. The composition according to claim 2 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.
7. The composition according to claim 2 , wherein said composition is in the form of a tablet.
8. The composition according to claim 7 , wherein said tablet has a weight between 300-500 mg.
9. The composition according to claim 6 , wherein said composition is in the form of a tablet.
10. The composition according to claim 9 , wherein said tablet has a weight between 300-500 mg.